Workers' Compensation Outcomes Following Minimally Invasive Transforaminal Lumbar Interbody Fusion performed in an Outpatient Surgery Center

Madhav Patel, Kevin C Jacob, James Nie¹, Timothy J Hartman, Omolabake Oyetayo¹, Eileen Zheng, Keith R. Macgregor², Kern Singh²

¹Rush University Medical Center, ²Midwest Orthopaedics At Rush

INTRODUCTION: While many spine studies have evaluated a Workers' Compensation (WC) population, few have investigated outcomes within an ambulatory surgical center (ASC) setting. We aim to assess postoperative outcomes between WC and non-WC patients undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) at an ASC.

METHODS: A single surgeon database was searched to locate patients undergoing single-level MIS TLIF at an ASC. Patients missing insurance status were excluded. Patients receiving surgery for trauma, infection, or cancer were also excluded. Patients were divided into two groups: WC vs. non-WC (private insurance). Demographic and perioperative characteristics were collected and compared with Student's t-test (continuous) and chi-squared test (categorical). Patient reported outcome measures (PROMs) were collected preoperatively and postoperatively. The following PROMs were used: VAS back, VAS leg, Oswestry Disability Index (ODI), 12-Item Short Form (SF-12) Physical Composite Score (PCS), and Patient Reported Outcome Measurement Information System physical function (PROMIS-PF). PROM scores were compared between groups using Student's t-test for independent samples. MCID achievement was determined based on change in PROM score from preoperative to postoperative meeting established cut-off values in literature. Achievement rates were compared between WC and non-WC groups with chi-squared test. RESULTS:

A total of 71 patients were included, 33 WC and 38 non-WC. Other than differences in age, gender, and ethnicity ($p \le 0.021$, all), no demographic characteristics significantly differed between groups. Almost half of the patients presented with degenerative spondylolisthesis (46.5%). Mean operative time was 122.0 minutes, mean estimated blood loss (EBL) was 42.8 milliliters (mL), and mean length of stay was 4.6 hours following surgery. Fusion rate at 1-year was 96.0% in the total cohort. Spinal pathology at presentation, perioperative measures, and fusion rates did not differ between groups. The WC cohort had significantly lower PROMIS-PF at 6-weeks/12-weeks, significantly higher VAS back from 6-weeks through 6-months, and significantly higher ODI from 6-weeks to 6-months ($p \le 0.033$, all). No differences were observed for VAS leg or SF-12 PCS. MCID achievement rates were significantly higher in the non-WC group for ODI at 6-weeks, 1-year, and overall, VAS back at 6-months and overall, and VAS leg at 12-weeks ($p \le 0.033$, all). Attainment rates were comparable between groups for PROMIS-PF and SF-12 PCS at all time points.

DISCUSSION AND CONCLUSION: Physical function PROMs and MCID achievements were largely comparable between WC and non-WC subjects. Leg pain scores were also similar between groups, but MCID attainment rates tended to be lower in the overall postoperative period for WC patients. In addition, WC suffered from higher back pain and disability,

and		lower			overall				NCID	achievement				rates			tor
Table 1. Patient Demographics			Table 2. Perioperative				Table 3. Mean Patient Reported Outcomes			Table 4. Minimum Clinically Important Difference							
Characteristic	Total (m=71)	WC (m=21)	Non-WC	*p-value	Characteristics		NHC .	N 1970	the sectors	PROM	WC Mann + SD	Non-WC Mann & SD	*†p-value	PROM	wc	Non WC	to value
Age (mean ±	(0-71)	(a=55)	(4-34)		Characteristic	(n=71)	(n=33)	(n=38)	-p-value	PROMIS PF	Areas 2 010	ortan x ob		FROM	*((n)	Non-WC	povalue
SD, years)	48.3±9.9	44.4±7.8	\$1.7±10.3	0.001	Spinal Pathology	(ii - 1)	(0.11)	(1. 1.)		Preoperative	36.4±6.4	38.014.4	0.386		70, (II)	70, (II)	
Gender				0.021	Degenerative					6-weeks	32.1±5.8	40.5±7.0	0.004	ODI			
Female	35.2% (25)	21.2% (7)	47.4% (18)		Spondylolisthesis	46.5% (33)	45.5% (15)	47.4% (18)	0.872	12-weeks 6 months	36.9#7.6	43,016,4	0.033	6-weeks	5.3%(1)	33.3% (7)	0.027
Ethnicity	04.875 (40)	78,879 (20)	32.0% (20)	0.002	Istrinic Secondulationhasis	15 25 (25)	30 325 (10)	30.5% (15)	0.420	1-year	41.2±8.9	44.2±5.6	0.454	12-weeks	26.7% (4)	52.6% (10)	0.127
Caucasian	58,8% (40)	38,7% (12)	75.7% (28)	6,767	rHNP	22.5% (16)	27.3% (9)	18.4% (7)	0.373	SF-12 PCS				in the second	26.004 (0)	66 mm (10)	0.050
African-					Central					Preoperative	30.2±5.8	33.2±7.5	0.112	6-months	36.8% (7)	66.7% (14)	0.059
American	4.4% (3)	6.5% (2)	2.7%(1)		Stenosis	91.6% (65)	93.9% (31)	89.5% (34)	0.609	6-weeks	31.4±7.8	34.7±8.7	0.257	1-year	11.1% (1)	62.5% (5)	0.027
Hispanic	30.9% (21)	51.6% (16)	13.5% (5)		Foraminal					12-weeks	31.0±7.8	36.4+7.8	0.088	Overall	34.6% (9)	65.5% (19)	0.022
Asian	1.5% (1)	0.0% (0)	2.7%(1)		Stenosis	81.7% (58)	81.8% (27)	81.6% (31)	0.979	6-months	33.1±10.1	40.8±11.2	0.083	PROVIDE DE			
Other	4.4% (3)	3.2%(1)	5.4% (2)	0.005	Operative Time					VAS back	36.5112.3	33,2110,8	0,808	PROMIS-PF			
Non Disketia	05.92/ (69)	00.05/ (20)	100.05/ (18)	0.058	(stean = SL);	122.0+20.2	125 1+22 0	110 5+18 6	0.261	Preoperative	67+23	5 8+2 7	0.209	6-weeks	16.7% (1)	40.0% (6)	0.306
Diabetic	4.2% (3)	9.1% (3)	0.0% (0)		Estimated Blood	10010-0010	100/1-00/0	117/0-100	0.001	6-weeks	5.7±1.7	2.4±2.0	<0.001	12-weeks	25.0%(2)	58.3%(7)	0.142
Smoking Status				0.127	Loss (Mean #					12-weeks	5.1±1.9	2.6±2.0	0.001	6 months	42.08/ (2)	50.08/ (7)	0.757
Non-Smoker	92.9% (65)	87.9% (29)	97.3% (36)		SD; mL)	42.8±24.1	38.0±22.3	46.9±25.2	0.160	6-months	5.3±2.6	2.9±2.3	0.005	0-montus	42.970 (3)	30.0% (7)	0.737
Smoker	7.1% (5)	12.1% (4)	2.7%(1)		Length of Stay					1-year	4.242.6	4.5±2.8	0.808	1-year	0.0% (0)	66.7% (4)	0.058
Hypertension					(Mean # SD;					VAS leg	53+29	5.0+2.9	0.716	Overall	45.5% (5)	60.0% (12)	0.436
Status				0.278	hours)	4.6±1.4	4.9±1.7	4.4±1.1	0.284	6-works	43+3.0	1.8+2.3	0.003	SE-12 PCS			
hypertensive	78.6%(55)	84.4% (27)	73 7% (28)		rosoperative vas					12-weeks	3.3±2.8	2.4±2.6	0.338	01-121-00			
Hypertensive	21.4% (15)	15.6% (5)	26.3% (10)		POD 0	5.0±2.5	5.1±2.4	4.8±2.7	0.738	6-months	3.5±2.8	2.2+2.6	0.165	6-weeks	33.5% (4)	50.0% (11)	0.350
ASA					Postoperative					1-year	2.0±1.9	3.2±3.0	0.320	12-weeks	18.2% (2)	50.0% (7)	0.100
Classification				0.650	Narcotic					ODI	44.2.12.8	41.4+10.0	0.026	6-months	45.5% (5)	54.6% (6)	0.670
<2	27.3% (18)	30.0% (9)	25.0% (9)		Consumption					6 monks	44.2113.8	91,9817.9 39 7417 A	0.336	1	CO 00((0)	40.00((2))	0.7(4
22	72.7% (48)	70.0% (21)	/5.0% (2/)		(OME)					12-weeks	38.3±12.9	24.1±15.5	0.006	1-year	50.0% (2)	40.0% (2)	0.764
(More + SD)	0.8+1.1	0.0+1.2	0.8+0.0	0.979	POD 0	22.0±17.1	24.2±17.6	20.2±16.7	0.3.56	6-months	37.3±17.8	21.8±16.4	0.005	Overall	55.6% (10)	64.0% (16)	0.576
Incurace	0,811.1	0.941.4	9.819.7	<0.001	1-year Authors durin	86.087.7345	01.28 (11)	100.08/ (13)	0.288	1-year	30.0±16.3	24.9±23.5	0.577	VAS back			
Workers'					WC = Workers' Com	ensation: non-Wi	" = nen-Workers' (Compensation: POD -	nostoperative	WC = Workers' Compen-	nsation; non-WC = non-W	orkers' Compensation		6 maake	36 8% (7)	61 09/ (13)	0.113
Compensation	46.5% (33)	100.0% (33)	0.0% (0)		day; mL = milliliters;	SD= standard dev	iation; rHNP = recu	arrent herniated nucle	us pulposus;	*p-values calculated usit	ng paired sample t-test to c	determine preoperative to	o postoperative	0-weeks	50.876(7)	01.976(13)	0.115
Private	53.5% (38)	0.0% (0)	100.0% (38)		OME - oral morphine	equivalents .				improvement in each col	hort			12-weeks	46.7% (7)	68.4% (13)	0.201
WC = Workers'	Compensation; non-	WC = non-Workers	Compensation; ASA	a = American	*p-values calculated u	sing Student's t-to	st for continuous v	ariables and chi-squa	re analysis for	†p-values calculated usin	ng Student's t-test to comp	sare mean PROMs betwee	en both cohorts	6-months	29.4% (5)	70.6% (12)	0.016
Society of Anest	hesiologists; CCI =	Charlson Comorbid	ity Index; SD= standa	rd deviation	categorical variables					Boldface indicates signi	feater			1-wear	44 494 (4)	57 194 (4)	0.614
Bootisee moleate	sugnineance				Boldface indicates sig	nificance											0.011
														Overall	38.5% (10)	70.4% (19)	0.020
														VAS leg			
														6-weeks	33.3% (6)	55.0% (11)	0.180
														12	28 (8/ (4)	((70/ (10)	0.033
														12-weeks	28.0% (4)	00.7%(12)	0.033
														6-months	50.0% (8)	37.5% (6)	0.476

both.

*p-values calculated using chi-s Boldface indicates significance